Your first 90 days
Your first 90 days on Uplizna for NMOSD
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Uplizna is given less often than most NMOSD treatments, but its start takes more planning. Three screening tests, any needed vaccines and an insurance approval come before the first infusion. Then 2 infusions arrive 2 weeks apart, and the next one is about 6 months away. This page lays out that stretch from the FDA label, Amgen's support program and one insurer's written rules.
What has to happen before the first bottle ships
Uplizna has no REMS, so the first infusion waits on 3 screening tests, any needed vaccines, an insurance approval and a place to receive it. These are the 7 things in the way, in order.
A hepatitis B blood test
The label requires hepatitis B screening before the first dose.
- Uplizna is not given to anyone with active hepatitis B. If a past infection or carrier status shows up, the label asks your neurologist to involve a liver specialist before and during treatment.FDA label
A tuberculosis check
The label asks your neurologist to check for active tuberculosis and test for a hidden (latent) infection.
- Uplizna is not given with active or untreated latent tuberculosis.
- An infectious disease specialist may weigh in on treating it first.FDA label
An antibody level test
The label requires a blood test of your immunoglobulin levels before the first dose.
- If your levels are low, it asks your neurologist to consult an immunology expert before starting.FDA label
Vaccines at least 4 weeks ahead
The label asks for all vaccines to be given by the usual guidelines at least 4 weeks before the first infusion.
- Live vaccines are not recommended during treatment or until your B cells recover after stopping.FDA label
Your other medicines
Tell your neurologist about every medicine that affects your immune system, including steroids and other NMOSD treatments.
- The label says using them together may raise the risk of infection.FDA label
Enrollment and the insurance check
You can call Amgen By Your Side, or your doctor's office can enroll you online with your consent.
- After you sign a HIPAA release, the team checks your coverage, your likely costs and whether a prior authorization is needed.Amgen insurance page
Where each infusion will happen
Amgen describes infusions at an infusion center or a doctor's office.
- It says home infusion may be an option, and to ask your doctor and your insurance about it.Starting Uplizna
The days that matter
Counted from the first infusion, with the screening tests and vaccine window before it, the second starting infusion on day 15 and the next dose about 6 months out. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Enrollment and the benefits check
The office or you enroll in Amgen By Your Side, and a Patient Access Liaison reviews your coverage.
- No source sets how long this takes, because each insurer works on its own timeline.
Hepatitis B, tuberculosis and antibody tests
All 3 are required before the first dose.
- Results that need a liver, infectious disease or immune specialist can add time before the first infusion.
Last day for vaccines
The label asks for any needed vaccines, live or not, at least 4 weeks before the first infusion.
- Ask your neurologist which vaccines you still need.
Approval, then booking the infusion
Once the plan approves, the first 2 infusions can be booked 2 weeks apart.
- Your liaison can help find an infusion center and set up appointments.
First infusion, 300mg
A steroid comes about 30 minutes before, with an antihistamine and a fever reducer 30 to 60 minutes before.
- The drip speeds up in steps over about 90 minutes, and staff watch you for at least 1 hour after.
Infusion reactions are most common with the first dose
Reactions such as headache, nausea, sleepiness, shortness of breath, fever, muscle aches, rash or a pounding heart can happen.
- The Medication Guide says to tell your healthcare provider right away.
Second starting infusion, 300mg
The same premedicines, the same 90 minutes and the same hour of watching.
- Before every infusion, the label asks staff to check for an active infection and to delay the dose until it clears.
B cells are down
In the main trial, B cell counts fell below normal by week 4 in every patient on Uplizna.
- They stayed below normal in 94% through week 28, which is why infections need attention.
Antibody levels over time
The label asks your neurologist to keep checking immunoglobulin levels during treatment.
- It sets no fixed schedule, and checks matter most if infections keep coming back.
Next dose about 6 months from day 1
The FEP policy below approves up to 9 vials in the first 12 months.
- At 3 vials per infusion, that covers both starting doses and the dose at month 6.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Uplizna label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Label dated September 21, 2026, read on DailyMed. FDA label
- September 2026
The FDA label added instructions for drawing Uplizna from the vial, using a fine needle and no vial spikes or closed transfer devices. The dose, tests and warnings did not change.FDA label
- December 2025
The FDA added generalized myasthenia gravis as a third use, with the same dose schedule. The warnings on infusion reactions and infections were updated with data from that trial.FDA letter
- April 2025
The FDA added IgG4-related disease as a second use. The NMOSD dose did not change.FDA letter
- June 2020
The FDA approved Uplizna for adults with NMOSD who are AQP4 antibody positive. It was the first approval for the drug.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- Two starting doses, then every 6 months
The label gives 300mg, then another 300mg 2 weeks later.
- After that, one 300mg infusion comes every 6 months, counted from the first infusion.FDA label
- The same dose for everyone
The dose does not depend on your weight.
- Each carton holds three 100mg vials, and all 3 go into one 250mL bag of salt water for a single infusion.FDA label
- Medicines before every infusion
The label calls for a steroid by IV, such as methylprednisolone, about 30 minutes before.
- It also calls for an antihistamine, such as diphenhydramine, and a fever reducer, such as acetaminophen, by mouth 30 to 60 minutes before.FDA label
- How the infusion is given
Uplizna goes into a vein through a pump and a filter, starting slowly and speeding up in 3 steps.
- It takes about 90 minutes in total.FDA label
- Passing the time
Amgen says infusions take place at an infusion center or doctor's office.
- It suggests bringing a book, or downloading a movie or podcast, for the visit.Uplizna NMOSD page
- Watching after each infusion
Staff watch you closely during the infusion and for at least 1 hour after it ends.
- If a reaction happens, they may slow or stop the infusion and treat your symptoms.
- A life-threatening reaction means Uplizna is stopped for good.FDA label
- Infections delay a dose
Before every infusion, staff check for an active infection.
- The label says to wait until it clears.
- Infections can still happen after your last dose, so keep reporting them.FDA label
- Pregnancy and birth control
Uplizna may harm an unborn baby, based on animal studies.
- The label advises effective birth control during treatment and for 6 months after the last infusion.
- A pregnancy registry takes calls at 1-303-724-4644.FDA label
- If you were on Uplizna while pregnant
Tell your baby's healthcare provider.
- The label says the baby should not get live vaccines until tests show the baby's B cells have recovered.FDA label
- Breastfeeding
It is not known whether Uplizna passes into breast milk.
- The Medication Guide asks you to talk with your healthcare provider about the best way to feed your baby.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs of an infusion reaction
Headache, nausea, sleepiness, shortness of breath, fever, muscle aches, rash or a pounding heart.
- The Medication Guide says to tell your healthcare provider right away.
- Reactions occurred in 9.3% of NMOSD trial patients, most often with the first infusion.FDA label
Signs of infection
Painful and frequent urination, a stuffy or runny nose, sore throat, fever, chills, cough or body aches.
- Tell your healthcare provider right away.
- Over the trial and its extension, 20% had a urinary tract infection.FDA label
Signs of PML, a rare brain infection
Weakness on one side of the body, clumsy arms or legs, vision changes, changes in thinking or memory, confusion or personality changes.
- Call your healthcare provider right away.
- The label says no confirmed case was found in Uplizna trials.FDA label
Hepatitis B coming back
If you have ever had hepatitis B, it may become active again during or after treatment and cause serious liver problems.
- The Medication Guide says your provider will monitor you if you are at risk.FDA label
Joint pain and other common side effects
In the NMOSD trial, urinary tract infection occurred in 11% on Uplizna against 10% on placebo.
- Joint pain occurred in 10% against 4%, and back pain in 7% against 4%.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedThe FEP policy below asks for age 18 or older and a positive AQP4 antibody test. It also asks for no active hepatitis B, no active or untreated latent tuberculosis and no live vaccines given at the same time. The neurologist's records usually answer what the plan is asking for.FEP Blue policy
- Screening results are missingHepatitis B, tuberculosis and antibody level results are required before the first dose. Amgen says your liaison can help with steps such as completing required labs and checking what the prior authorization still needs.Amgen insurance page
- The plan says no after reviewAmgen describes 2 next steps. Your doctor can ask for a medical exception with extra paperwork, or you and the office can appeal. The Amgen By Your Side team can explain both.Amgen insurance page
- A copay you cannot payCommercial insurance: the Amgen Commercial Co-Pay Program, as little as $0 for Uplizna and infusion costs, with program maximums. Medicare, Medicaid, VA, TRICARE and other government coverage are excluded. Our help paying page lists charity funds that may cover what remains.Amgen financial support
- You live in Massachusetts or Rhode IslandAmgen's co-pay terms say residents of these 2 states are not eligible for administration support. Help with the medicine itself may still apply, so the clinic fee may fall on you.Amgen financial support
- Medicare, Medicaid or no insuranceThe co-pay program does not apply. Amgen lists independent funds such as The Assistance Fund, Good Days, the PAN Foundation and NORD. Each sets its own rules, and Amgen does not run them.Amgen financial support
- The renewal after a yearThe FEP policy renews for 12 months at a time, with 6 vials, when your neurologist documents a benefit such as fewer relapses. Ask the office when the renewal is due so the 6-month dose is not delayed.FEP Blue policy
Blue Cross Blue Shield Federal Employee Program prior authorization policy, April 1, 2026
- Age 18 or older
- Neuromyelitis optica spectrum disorder with a positive anti-aquaporin-4 (AQP4) antibody test
- No active hepatitis B infection
- No active or untreated latent tuberculosis
- Not given at the same time as live vaccines
- Females who could become pregnant are advised to use effective birth control during treatment and for 6 months after the last dose
Approval length. Twelve months at first, up to 9 vials. Renewals are 12 months at a time, up to 6 vials, when the neurologist documents a clinical benefit such as fewer relapses.
This policy was approved on March 6, 2026 and cites the December 2025 label. It predates the September 2026 label, which changed only how pharmacists draw the medicine from the vial. Nothing in it conflicts with the current label. It is here as an example of what a plan asks for, not as a rule. FEP Blue policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A dedicated Patient Access Liaison who explains insurance, costs and appointments, and helps find an infusion center
- A benefits investigation after you sign a HIPAA release: what your plan covers, your likely costs and whether a prior authorization is needed
- The Amgen Commercial Co-Pay Program, as little as $0 for Uplizna and infusion costs for eligible commercial insurance, with program maximums Uplizna HCP site
- Co-pay help is not open to Medicare, Medicaid, Medigap, VA, CHAMPUS, DOD, TRICARE or other government coverage, under the program's terms
- Residents of Massachusetts or Rhode Island are not eligible for the infusion administration part of the co-pay help Amgen financial support
- A list of independent charity funds Amgen financial support
- NMOSD Peer Mentors, Uplizna patients who volunteer to talk about their own experience Personalized support
Details as the drugmaker publishes them. Amgen By Your Side
Five questions for the pharmacist or the support line
- Are my hepatitis B, tuberculosis and antibody level results already on file with the infusion center?
- Which vaccines do I still need, and is there time to get them 4 weeks before my first infusion?
- Will I get my steroid, antihistamine and fever reducer at the infusion center, or do I take some at home first?
- How long should I plan to stay, counting the premedicines, the 90-minute infusion and the hour of watching?
- Has my co-pay program been applied to both the medicine and the infusion fee?
- Who books my 6-month infusion, and when does my insurance approval need renewing?
Questions people ask in the first weeks
How long does it take to start Uplizna after it is prescribed?
There is no fixed number of days. Three screening tests, any needed vaccines 4 weeks ahead, the benefits check, prior authorization and booking an infusion site each take their own time. Your Patient Access Liaison can update you on the insurance review as it moves.
How often is Uplizna given for NMOSD?
Twice a year after 2 starting doses. The label gives 300mg, then another 300mg 2 weeks later, then one 300mg infusion every 6 months counted from the first infusion.
What tests do I need before my first Uplizna infusion?
The label requires hepatitis B screening, a check for active and latent tuberculosis and a blood test of immunoglobulin levels. Uplizna is not given with active hepatitis B or active or untreated latent tuberculosis.
Do I need vaccines before starting Uplizna?
The label asks for all vaccines by the usual guidelines at least 4 weeks before the first infusion. Live vaccines are not recommended during treatment or until your B cells recover after stopping.
Why do I get medicines before each infusion?
The label calls for a steroid, an antihistamine and a fever reducer before every infusion to make infusion reactions less frequent and less severe. In the NMOSD trial, reactions occurred in 9.3% of patients, most often with the first infusion.
Is Uplizna approved if I do not have AQP4 antibodies?
No. The NMOSD approval covers adults who are AQP4 antibody positive. The label says there was no evidence of benefit in the 17 AQP4-negative trial patients.
Can I keep taking my other NMOSD medicines?
Ask your neurologist. In the main trial, other immune-suppressing drugs were not allowed during the blinded period, and the label says combining them may raise the risk of infection.
Is Uplizna used for other conditions?
Yes, the label also covers IgG4-related disease and generalized myasthenia gravis in adults, with the same dose schedule. This page covers only NMOSD.
Free email alert
Hear when the Uplizna label changes
One email the day the FDA revises the Uplizna label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Uplizna only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Neuromyelitis optica spectrum disorder (NMOSD) for new trials, FDA decisions and label changes for every treatment.
Sources
- DailyMed - UPLIZNA- inebilizumab injection (prescribing information revised September 2026, SPL version 11, and Medication Guide), Horizon Therapeutics USA (Amgen), via DailyMed, September 21, 2026.
- Cost, Savings, and Support | UPLIZNA® (inebilizumab-cdon), Amgen, November 7, 2026.
- UPLIZNA® Insurance Coverage | Amgen By Your Side, Amgen, November 7, 2026.
- UPLIZNA® Financial Support Programs | Amgen By Your Side, Amgen, November 7, 2026.
- Frequently Asked Questions (FAQs) for UPLIZNA® | Amgen By Your Side, Amgen, November 7, 2026.
- NMOSD: Starting UPLIZNA® (inebilizumab-cdon) | UPLIZNA®, Amgen, November 7, 2026.
- NMOSD Treatment | UPLIZNA® (inebilizumab-cdon), Amgen, November 7, 2026.
- NMOSD Personalized Support | UPLIZNA® (inebilizumab-cdon), Amgen, November 7, 2026.
- UPLIZNA® (inebilizumab-cdon) | Healthcare Professional Home, Amgen, November 7, 2026.
- Pharmacy Policy 5.99.018, Uplizna, Blue Cross Blue Shield Federal Employee Program, April 1, 2026.
- BLA 761142/S-004 supplement approval letter, generalized myasthenia gravis, FDA, December 11, 2025.
- BLA 761142 approval letter, Uplizna (inebilizumab-cdon) for NMOSD, FDA, June 11, 2020.
- BLA 761142/S-003 supplement approval letter, immunoglobulin G4-related disease, FDA, April 3, 2025.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing neurologist. Found an error? Use the report link in the footer and it will be checked against the source.